Skin Infection News and Research

RSS

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).

25 Apr 2015

TSRI scientists uncover unique mechanism of natural product with antimicrobial, anti-cancer effects

Scientists from the Florida campus of The Scripps Research Institute have uncovered the unique mechanism of a powerful natural product with wide-ranging antifungal, antibacterial, anti-malaria and anti-cancer effects.

1 Apr 2015

New study sheds light on natural small molecule with antimicrobial effects

31 Mar 2015

Two common antibiotic treatments equally effective against MRSA skin infections

Researchers funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have found that two common antibiotic treatments work equally well against bacterial skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA) acquired outside of hospital settings.

20 Mar 2015

Study shows that households can serve as reservoir for transmitting MRSA

Households can serve as a reservoir for transmitting methicillin-resistant Staphylococcus aureus (MRSA), according to a study published this week in mBio, the online open-access journal of the American Society for Microbiology. Once the bacteria enters a home, it can linger for years, spreading from person to person and evolving genetically to become unique to that household.

10 Mar 2015

Salt may help control infection

Researchers at Vanderbilt University and in Germany have found that sodium - salt - accumulates in the skin and tissue in humans and mice to help control infection.

4 Mar 2015

Synthetic compound shows antibiotic action against MRSA

Microbiologists and chemists at the University of South Florida have developed and patented a synthetic compound that has shown antibiotic action against methicillin resistant Staphylococcus aureus, also known as MRSA, which can cause many serious infections and deaths.

30 Jan 2015

Debiopharm receives FDA Fast Track designation for anti-infectious agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced that the US Food and Drug Administration granted Fast Track designation to its anti-infectious agent Debio 1450, a highly potent antibiotic specifically active against all Staphylococcus species.

8 Jan 2015

Fat cells below skin help protect from bacteria, say researchers

When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the University of California, San Diego School of Medicine report the surprising discovery that fat cells below the skin help protect us from bacteria.

2 Jan 2015

Study: Using wash cloths treated with skin cleanser could reduce skin infections in U.S. jails

New research shows providing detainees wash cloths treated with a skin cleanser could reduce the prevalence of Staphylococcus aureus (S. aureus) bacteria in U.S. jails. Researchers looked at the effect on transmission of S. aureus of using wash cloths treated with chlorhexidine gluconate (CHG) compared with wash cloths with only plain water in detainees at Dallas County Jail.

25 Nov 2014

NPS MedicineWise calls all Australians to join the fight against antibiotic resistance

As Antibiotic Awareness Week 2014 is held across Australia from 17-23 November, NPS MedicineWise is asking all Australians to imagine a world without antibiotics and join the fight against antibiotic resistance.

17 Nov 2014

Nearly half of hog workers carry livestock-associated bacteria to home

A new study suggests that nearly half of workers who care for animals in large industrial hog farming operations may be carrying home livestock-associated bacteria in their noses, and that this potentially harmful bacteria remains with them up to four days after exposure.

9 Sep 2014

Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food & Drug Administration.

1 Sep 2014

Researchers report that predominant CA-MRSA strain migrated from sub-Saharan Africa

The predominant strain of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infecting people in Europe, the Middle East and northern Africa derived from a single sub-Saharan ancestor, a team of international researchers reported this week in mBio-, the online open-access journal of the American Society for Microbiology.

26 Aug 2014

New nanosheets can cling to body's most difficult-to-protect contours and keep bacteria at bay

Wrapping wound dressings around fingers and toes can be tricky, but for burn victims, guarding them against infection is critical.

11 Aug 2014

Dermatologist warns about safety of children's skin care products

Before the advent of Internet search engines, parents obtained much of their medical advice from their child's doctor.

8 Aug 2014

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.

12 Jun 2014

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

9 Jun 2014

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

In the battle against stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), a new single-dose antibiotic is as effective as a twice-daily infusion given for up to 10 days, according to a large study led by Duke Medicine researchers.

5 Jun 2014